Anti-IgE treatment of eosinophil-associated gastrointestinal disorders
- 1 September 2007
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 120 (3), 594-601
- https://doi.org/10.1016/j.jaci.2007.06.015
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Potential of Blood Eosinophils, Eosinophil-Derived Neurotoxin, and Eotaxin-3 as Biomarkers of Eosinophilic EsophagitisClinical Gastroenterology and Hepatology, 2006
- Eosinophilic esophagitis: Pathogenesis, genetics, and therapyJournal of Allergy and Clinical Immunology, 2006
- Evidence of in vivo basophil activation in chronic idiopathic urticariaClinical and Experimental Allergy, 2006
- Evaluation of basophil activation in food allergy: present and future applicationsCurrent Opinion in Allergy and Clinical Immunology, 2006
- The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammationJournal of Allergy and Clinical Immunology, 2005
- Omalizumab-induced reductions in mast cell FcεRI expression and functionJournal of Allergy and Clinical Immunology, 2004
- Eosinophilic gastrointestinal disorders (EGID)☆Journal of Allergy and Clinical Immunology, 2004
- Human dendritic cell 1 and dendritic cell 2 subsets express FcεRI: Correlation with serum IgE and allergic asthmaJournal of Allergy and Clinical Immunology, 2003
- Omalizumab treatment downregulates dendritic cell FcεRI expressionJournal of Allergy and Clinical Immunology, 2003
- Spontaneous Release of Histamine from Basophils and Histamine-Releasing Factor in Patients with Atopic Dermatitis and Food HypersensitivityNew England Journal of Medicine, 1989